# SEP 2 9 2004 E

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

olicants : Miri Seiberg et al.

Serial No.: 09/621,565

Art Unit: 1615

Filed

: July 21, 2000

Examiner: Blessing M. Fubara

For

: REDUCING HAIR GROWTH, HAIR FOLLICLE AND HAIR SHAFT

SIZE AND HAIR PIGMENTATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

- 1 - - - 11

Andrea L. Colby (Name of applicant, assignee, or Registered Representative)

(Signature)

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### SEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on February 13, 2002, June 17, 2002, May 12, 2003, February 12, 2003, February 19, 2003, May 20, 2003, and March 2, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
The accordance with S1 120(a) this Information
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with $\Box$ the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

 $\boxtimes$  In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final

Action under §3	1.113 or a Notice of Allowance under §1.311, or
an action that	otherwise closes prosecution and that it is
accompanied by	one of:
	Statement in Accordance with §1.97(e)
	(attached); or
$\boxtimes$	Please charge Deposit Account No. 10-
	0750/JBP510/ALC the fee of \$180.00 as set forth
	in §1.17(p).
☐ In a	ccordance with §1.97(d), this Information
Disclosure Sta	tement is being filed after the mailing date of
either a Final	Action under §1.113 or a Notice of Allowance
 under §1.311	out before the payment of the Issue Fee.
Applicant(s) he	ereby petition(s) for consideration of this
Information Dia	sclosure Statement. Included are: Statement in
Accordance with	h §1.97(e) as set forth below and the fee of
<u>\$180.00</u> as set	forth in §1.17(p).
⊠ Copi	es of each of the references listed on the
attached Form	PTO-1449 are enclosed herewith.
☐ Copi	es of references listed on the attached Form PTO-
1449 are enclo	sed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
☐ Copi	es of only foreign patent documents and non-
patent literat	ure are enclosed in accordance with 37 CFR 1.98
(a)(2). (The	U.S. patents and each U.S. patent application
•	

.

publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

 $\hfill \Box$  There are no listed references which are not in the English language.

 $\boxtimes$  The relevance of those listed references which are not in the English language is as follows:

EP 0476311 A1 English language claims are provided from the EP 0476311 B1 document. EP 0643083 A1 English language abstract and claims are provided from the EP 0643083 B1 document.

English language abstracts are provided for FR 2596986, FR 2616696, FR 2685202, JP 6145061, JP 6192085, JP 7010772, JP 7196527, JP 7196529, JP 8040824, JP 8059450, JP 8143442, JP 8333260, JP 9077638, JP 9176033, JP 59187756 and KR 92-8853.

English language translations are provided for FR 2811226, JP 1096106, JP 5015574, JP 7304655, JP 8012560, JP 9025212, JP 902514, JP 11346695, JP 62036304, WO 96/40121, WO 99/09065 and WANG et al Gut 19:260-266 (1978).

English language equivalents are provided for:

EP 0643960 - US 5,741,496

EP 0655 470 - US 5,712,356 & 5,936,052

EP 0661037 - US 5,629,015

EP 0814116 - US 5,871,823

JP 5114905 - EP 0508886

WO 87/07838 - US 4,978,528

WO 98/33089 - US 6,018,001

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JBP0510/ALC. This form is submitted in triplicate.

Respectfully submitted,

Andrea L. Colby

Reg. No. 30,194

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2792 DATED: Sept. 27, 2504

- 5 -

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

stitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 7

a concension of information unless it displaye a valid office contact number.				
Application Number	09/621,565			
Filing Date	07/21/2000			
First Named Inventor	Miri Seiberg			
Group Art Unit	1615			
Examiner Name	Blessing M. Fubara			
Attorney Docket Number	JBP0510			

U.S. PATENT DOCUMENTS

		U.S. Patent Document		6 ( 6 )	D	
Examiner Initials	Cite No. <sup>1</sup>	1	d Code <sup>2</sup> known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		3,097,947	Α	Kemmerer	07-16-1963	
		4,056,637	Α	Hagiwara et al	11-01-1977	
		4,434,095	Α	Chipens et al.	02-28-1984	
- "		4,477,434	Α	Kosaka	10-16-1984	
		4,978,528	Α	Degre	12-18-1990	
		5,057,417	Α	Hammonds et al.	10-15-1991	
		5,322,839	Α	Voegeli	06-21-1994	
		5,503,832	Α	De Stoutz	04-02-1996	
		5,505,946	Α	Kennedy et al.	04-09-1996	
		5,681,571	Α	Homgren et al.	10-28-1997	
		5,683,380	Α	Eckhouse et al.	11-04-1997	
		5,688,763	Α	Hammonds, Jr. et al.	11-18-1997	
		5,712,356	Α	Bothe et al.	01-27-1998	
		5,720,772	Α	Eckhouse	02-24-1998	
		5,871,823	Α	Anders et al.	02-16-1999	
		5,871,480	Α	Tankovich	02-16-1999	
		5,936,052	Α	Bothe et al.	08-10-1999	
		5,972,355	Α	Knight et al.	10-26-1999	
		6,017,549	Α	Knight et al.	01-25-2000	
		6,018,001	Α	Hiratani et al.	01-25-2000	
		6,045,548	Α	Furumoto et al.	04-04-2000	
		6,080,393	Α	Liu et al.	06-27-2000	_
		6,126,933	Α	Warne et al.	10-03-2000	
		6,183,762	B1	Deckers et al.	02-06-2001	
		6,217,572	B1	Tobinick	04-17-2001	
		6,272,883	B2	Bruder et al.	08-14-2001	
		6,273,885	B1	Koop et al.	08-14-2001	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of the Paperwork Reduction collection of information unless it displays a valid OMB control number

ATE: Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 7

de Concessor of information directs it displays a valid only contact flames.				
Application Number	09/621,565			
Filing Date	07/21/2000			
First Named Inventor	Miri Seiberg			
Group Art Unit	1615			
Examiner Name	Blessing M. Fubara			
Attorney Docket Number	JBP0510			

**U.S. PATENT DOCUMENTS** 

		U.S. Patent Document				
Examiner Initials	Cite No.1			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6,358,242	B1	Cecchetti	03-19-2002	·
		6,413,546	B1	He et al.	07-02-2002	
		6,433,025	B1	Lorenz	08-13-2002	
		6,461,348	B1	Bertan et al.	10-08-2002	
		6,485,484	B1	Connors et al.	11-26-2002	
		6,544,255	B2	Stewart	04-08-2003	
		6,558,656	B2	Mann	05-06-2003	-
		2004/0009142	A1	Zambaux et al.	01-15-2004	_

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 7

a conection of information unless it displays	a valid Olvib control number.
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

**FOREIGN PATENT DOCUMENTS** 

		Foreigr	n Patent Documen		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant passages	
Examiner Initials	er Cite  No.¹ Office³ Number⁴  KindCode⁵		Applicant of Cited Document	Cited Document mm-dd-yyyy	or relevant figures appear	T <sup>6</sup>		
		EP	0 341 745	A1	FIDIA S.p.A.	11-15-1989		
		ΕP	0 393 532	A2	Schering Corporation	10-24-1990		
		EP	0 476 311	A1	De Stoutz	03-25-1992	English Claims from B1 Document	No
		EP	0 508 886	A1	Digital Equipment Corporation	10-14-1992	=JP 5114905	
		EΡ	0 574 352	A1	Ciba-Geigy AG	12-15-1993		
		EP	0 643 083	A1	Essilor International	03-15-1995	English Abstract and Claims from B1 Document	No
		EP	0 643 960	A1	Laboratoire de Biologie Vegetale Yves Rocher	03-22-1995	=US 5,741,496	No
		EP	0 655 470	A1	Ciba-Geigy AG	05-31-1995	=US 5,712,356 & 5,936,052	No
		EP	0 661 037	A1	L'Oreal	07-05-1995	=US 5,629,015	No
		EP	0 713 106	A1	Menicon Co., Ltd.	05-22-1996		
		EP	0 758 687	A1	Ciba-Geigy AG	02-19-1997		
		EP	0 814 116	A1	Huls AG	12-29-1997	=US 5,871,823	No
		EP	0 963 761	A1	J&J Vision Products	12-15-1999	VTN0410	
		EΡ	1 192 938	A2	J&J Consumer Products Inc.	04-03-2002	JBP0523	
		EP	1 236 402	A2	J&J Consumer Products Inc.	09-04-2002	J&J2001	
		EP	1 236 465	A2	J&J Consumer Products Inc.	09-04-2002	J&J2002	
		FR	2 596 986	A1	Sederma SA (FR)	10-16-1987	English Abstract	No
		FR	2 641 696	A1	Sederma SA (FR)	07-20-1990	English Abstract	No
		FR	2 685 202	A1	Sederma SA (FR)	06-25-1993	English Abstract	No
		FR	2 811 226	A1	Clarins Laboratoires	01-11-2002		Yes
		JP	1096106	Α	Shiseido Company, Ltd	04-14-1989	-	Yes
		JP	5015574	Α	Japan Atom Energy Res Inst, et al.	01-26-1993		Yes
		JP	5114905	Α	Digital Equipment Corp.	05-07-1993	=EP 0 508 886	No
-		JP	6145061	Α	Fuji Seiyu KK	05-24-1994	English Abstract	No
		JP	6192085	Α	Inada Y	07-12-1994	English Abstract	No
		JP	7010772	Α	Fuji Seiyu KK	01-13-1995	English Abstract	No

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a ollection of information unless it displays a valid OMB control number.

e for form 1449A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 4 of 7

a collection of information unless it displays a	Tana OND Condoi Hambor.
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

#### FOREIGN PATENT DOCUMENTS

F	Cite	Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited	Pages, Columns, Lines, where relevant passages or relevant figures	6
Examiner Initials	No.1	Office <sup>3</sup> KindCo	Number⁴ ide <sup>5</sup>		Applicant of Cited Document	Document mm-dd-yyyy	appear	T⁵
		JP	7196527	Α	Morinaga Milk Ind. Co. Ltd.	08-01-1995	English Abstract	No
		JP	7196529	Α	Morinaga Milk Ind. Co. Ltd.	08-01-1995	English Abstract	No
		JP	7304655	Α	Kikkoman Corp.	11-21-1995		Yes
		JP	8012560	Α	Shiseido Company, Ltd.	01-16-1996		Yes
		JP	8040824	Α	Nonogawa Shoji:KK	02-13-1996	English Abstract	No
		JP	8059450	Α	Kose Corporation	03-05-1996	English Abstract	No
		JP	8143442	Α	Kikkoman Corp.	06-04-1996	English Abstract	No
		JP	8333260	Α	Kaminomoto Honpo:KK	12-17-1996	English Abstract	No
		JP	9025212	Α	Shiseido Co. Ltd.	01-28-1997		Yes
		JP	9025214	Α	Shiseido Co. Ltd.	01-28-1997		Yes
_		JP	9077638	Α	Art Beauty Clinic KK	03-25-1997	English Abstract	No
		JP	9176033	Α	Pigeon Corp.	07-08-1997	English Abstract	No
,		JP	11346695	Α	National Food Res. Inst. Ryookoku Shoji KK	12-21-1999		Yes
		JP	59187756	Α	Erika KK	10-24-1984	English Abstract	No
		JP	62036304	Α	Kashiwa Chemical Industries	02-17-1987		Yes
		KR	92-8853	В	Song	10-10-1992	English Abstract	No
		wo	87/07838	A1	Societe Bio Serae Sarl	12-30-1987	=US 4,978,528	No
		wo	91/04283	A1	Chang et al.	04-04-1991		
		wo	92/09639	A2	Bausch & Lomb Incorporated	06-11-1992		
		wo	92/09650	A1	Bausch & Lomb Incorporated	06-11-1992		
		wo	94/06485	A1	Ciba-Geigy AG	03-31-1994		
		wo	95/04609	A1	Ciba-Geigy AG	02-16-1995		
		wo	95/09002	A1	University of Pennsylvania	04-06-1995		
		wo	95/09011	A1	University of Pennsylvania	04-06-1995		
		wo	96/24392	A1	Fidia Advanced Biopolymers	08-15-1996		
		wo	96/40121	A1	Taisho Pharmaceutical Co. Ltd.	12-19-1996		Yes

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SE JOS JUNE SERVICE SE

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 5 of 7

a collection of information unless it displays a	Valid Civid Control Humber.
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

FOREIGN F	PATENT DO	CUMEN	112

Examiner Initials		Foreigr	Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant passages	
	Cite No. <sup>1</sup>	Office <sup>3</sup> KindCo			Applicant of Cited Document	Cited Document mm-dd-yyyy	or relevant figures appear	T <sup>6</sup>
		wo	96/40199	A1	University of Pennsylvania	12-19-1996		
		wo	97/18904	A1	Massachusetts Institute of Technology	05-29-1997		
		wo	98/01107	A1	Industria E Comercio de Cosmeticos Natura	01-15-1998		
		wo	98/02138	A1	Industria E Comercio de Cosmeticos Natura	01-22-1998		
		wo	98/17246	A1	ROC	04-30-1998		
		wo	98/33089	A1	Menicon Co., Ltd.	07-30-1998	=US 6,018,001	No
		wo	99/09065	A1	Eberhard-Karls-Univ.	02-25-1999		Yes
		wo	99/15917	A1	Novartis AG	04-01-1999		
		wo	99/57178	A1	Bausch & Lomb Incorporated	11-11-1999		
		wo	00/43049	A1	Pharmacia & Upjohn Company	07-27-2000		
		wo	01/34099	A1	J&J Consumer Products Inc.	05-17-2001	JBP0518	
		wo	01/35920	A1	Hindustan Lever Limited	05-25-2001		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		"A Combined Soybean Crushing-Deordorizing System that Yields 100-200 Mesh Powder for Food Additive Use has been Developed by SHINYU ZOKI CO. LTD. And MITSUBISHI RAYON ENGINEERING LTD.", <i>Tech Times</i> , pp 10 (1978).	
		"Soy Protein Prevents Skin Tumors From Developing in Mice", Gene Therapy Weekly, ISSN 1078-2842, pp 21 (November 8, 2001).	
		"Soy Therapy", www.wiseessentials.com/soytherapy.html (email from Jue-Chen Liu, Ph.D. to Cunero et al dated April 13, 2000) WISE ESSENTIALS.	
		BABIARZ-MAGEE ET AL, "The Expression and Activation of Protease-Activated Receptor-2 Correlate with Skin Color", Pigment Cell Res, Vol. 17 (2004) pp 241-251.	
		BADASH ET AL, "Effect of Gamma Irradiation of Field and Storage Fungi of Wheat, Maize and Soybean", Chemie Mikrobiologie Technologie der Lebensmittel (1992).	
		BLACKHEART ET AL, "Ligand Cross-Reactivity Within the Protease-Activated Receptor Family", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 28, pp 16466-16471 (1996)	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

PATENT Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 6 of 7

a collection of information unless it displays a	Valla OMB control number.
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GALVEZ ET AL, "Chemopreventive Property of a Soybean Peptide (Lunasin) That Binds to Deacetylated Histones and Inhibits Acetylation", <i>Cancer Research</i> , Vol. 61, No. 20, pp 7473-7478 (October 15, 2001).	
		HAFEZ ET AL, "Effects of Gamma Irradiation on Proteins and Fatty Acids of Soybean", Journal of Food Science, Vol. 50 (1985) pp 1271-1274.	
		HATTORI ET AL, "Effects of sup.60 Co- gamma-rays on Defatted Soybean Powder", Food Irradiation, Vol. 3, No. 1, pp 104-110 (1968).	
		HERMANNS ET AL, "Unraveling the Patterns of Subclinical Pheomelanin-Enriched Facial Hyperpigmentation: Effect of Depigmenting Agents", <i>Dermatology</i> , Vol. 201 (2000) pp 118-122.	
		HOLLENBERG ET AL, "Proteinase-Activated Receptor-2 in Rat Aorta: Structural Requirements for Agonist Activity of Receptor-Activating Peptides", <i>Molecular Pharmacology</i> , Vol. 49, pp 229-233 (1996).	
		JINGTIAN ET AL, "Studies of Soy Sauce Sterlization and its Special Flavour Improvement by Gamma-Ray Irradiation", Radiation Physics and Chemistry, Vol. 31, Nos 1-3, pp 209-213 (1988)	
		KENNEDY ET AL, "Prevention of Carcinogenesis by Protease Inhibitors", Cancer Research, Vol. 54, No. 7 (Suppl), pp 1999s-2005s (April 1, 1994).	
		KENNEDY, "The Evidence for Soybean Products as Cancer Preventive Agents", <i>The Journal of Nutrition</i> , Vol. 125, No. 3 Suppl, pp 733s-743s (March 1995).	
		KOVACS ET AL, "Effect of Irradiation and Dielectric Heating on Soybean Ultrastructure, Trypsin Inhibitor, and Lipoxygenase Activities", Food Structure, Vol. 10, pp 217-227 (1991)	
		LAM ET AL, "Combined Effect of Irradiation and Dielectric Heating on Chemical Properties of Soybeans", 7th Symp. On Radiation Chemistry, pp 477-483 (1990)	
		LIU ET AL, "Application of Soy in Skin Care", Journal Nutr., Vol. 132 (2002) pp 574S.	
		Merck Index (12th Edition), Edited by Susan Budavari (1996) Thrombin., entry 9525, p 1601.	
		Merck Index (12th Edition), Edited by Susan Budavari (1996) Trypsin, entry 9926, p 1669.	
		MYSLIBORSKI ET AL, "Therapy for Acne Vulgaris", Comprehensive Therapy, Vol. 7, No. 1, pp 13-16 (January 1981).	
		ODANI ET AL, "Studies on Soybean Trypsin Inhibitors. XIII. Preparation and Characterization of Active Fragments from Bowman-Birk Proteinase Inhibitor", <i>Journal Biochem.</i> , Vol. 83, No. 3, pp 747-753 (1978).	
		PAINE ET AL, "An Alternative Approach to Depigmentation by Soybean Extracts via Inhibition of the PAR-2 Pathway", <i>Journal Investigative Dermatology</i> , Vol. 116 (2001) pp 587-595.	
		SCOTT ET AL, "Protease-Activated Receptor 2, a Receptor Involved in Melanosome Transfer, is Upregulated in Human Skin by Ultraviolet Irradiation", <i>Journal Investigative Dermatology</i> , Vol. 117 (2001) pp 1412-1420.	

1	Examiner	 Date	
	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Reduction Act of 1995, no persons are required to respond to a control of the Paperwork Reduction Reduction

stitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 7 of 7

a collection of information unless it displays a	Valid OND CONTO Hamber.
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

		Sheet 7 of 7	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	r
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
		SCOTT ET AL, "Proteinase-Activated Receptor-2 Stimulates Prostaglandin Production in	ļ
		Keratinocytes: Analysis of Prostaglandin Receptors on Human Melanocytes and Effects of	
		PGE2 and PGF2a on Melanocyte Dendricity", Journal Investigative Dermatology, Vol. 122	Ī
		(2004) pp 1214-1224.	
		SCOTT ET AL, "The Proteinase-Activated Receptor-2 Mediates Phagocytosis in a Pho-	<del>                                     </del>
		Dependent Manner in Human Keratinocytes", <i>Journal Investigative Dermatology</i> , Vol. 121	
		(2003) pp 529-541.	ļ. <u></u> .
		SEIBERG ET AL, "Inhibition of Melanosome Transfer Results in Skin Lightening", Journal	
		Investigative Dermatology, Vol. 115 (2000) pp 162-167.	
		SEIBERG ET AL, "Soy Extracts Reduce Hair Growth and Hair Follicle Dimensions", Hair	
		Science and Technology, D. Van Neste (editor) (2003) pp 391-400.	
		SEIBERG ET AL, "Soymilk Reduces Hair Growth and Hair Follicle Dimensions", Experimental	
		Dermatology, Vol. 10 (2001) pp 405-423.	
		SEIBERG ET AL, "The Protease-Activated Receptor 2 Regulates Pigmentation via	
			Į.
		Keratinocyte-Melanocyte Interactions", Experimental Cell Research, Vol. 254 (2000) pp 25-32.	
		SEIBERG ET AL, "The Protease-Activated Receptor-2 Regulates Pigmentation via	1
		Melanosome Phagocytosis", Mechanisms of Suntanning, J. P. Ortonne and R. Ballotti (editors)	
		(2002) pp 215-278.	
		SEIBERG ET AL, "The Regulation of Pigmentation by Serine Proteases and Their Inhibitors",	1
		Inhibition of Human Proteases: From Target Identification to Therapy, CHI Press (1998) pp 1-3.	
		SEIBERG, "Keratinocyte-Melanocyte Interactions During Melanosome Transfer", Pigment Cell	
		Res., Vol. 14 (2001) pp 236-242.	
	<del></del>	SESSA ET AL, "Toasted Soybean Flour Components with Trypsin Inhibitor Activity", JAOCS,	<del></del>
		Vol. 63, No. 6, pp 784-788 (June 1986)	
		SHARLOW ET AL, "The Protease-Activated Receptor-2 Upregulates Keratinocyte	
		Phagocytosis", Journal of Cell Science, Vol. 113 (2000) pp 3093-3101.	
		SONG ET AL, "PS04.01.44 Crystal Structure of the Complex of Porcine Pancreatic Trypsin with	
		Kunitz-Type Soybean Trypsin Inhibitor", Crystallography of Biological Macromolecules, p. C-	
		106, XVII Congress and General Assembly of the International Union of Crystallog, (1996) (	
		www.bmsc.wahingts/abstracts/S0081.html)	
		TAN-WILSON, "Relevance of Multiple Soybean Trypsin Inhibitor Forms to Nutritional Quality",	
		Nutritional and Toxicological Significance of Enzyme Inhibitors in Foods, Edited by Mendel	
		Friedman, Chapter 22, pp 391-411 (1985), Department of Biological Sciences, State University	
		of New York at Binghamton.	
		VAN DEN BROEKE ET AL, "Topically Applied N-acetylcysteine as a Protector Against UVB-	
	[	Induced Systemic Immunosuppression", Journal of Photochemistry and Photobiology, B:	1
		Biology, Vol. 27, pp 61-65 (1995).	
		WANG ET AL, "Effects of Soybean Trypsin Inhibitor on Digestive Physiology and Growth and	
		Development of Helicoverpa Armigera Larvae", Acta Entomologica Sinica, Vol. 38, No. 3	Yes
		(August 1995) pp 272-274.	
	·	WENNINGER ET AL (Editors), International Cosmetic Ingredient Dictionary and Handbook,	
		Seventh Edition, Vol. 2 (1997) pp 1626, 1654-1661, 1693-1697, published by The Cosmetic,	
		Toiletry, and Fragrance Association, Washington DC	+
		WILSON ET AL, "Immunocytochemical Study of the Interaction of Soybean Trypsin Inhibitor	
		with Rat Intestinal Mucosa", <i>Gut</i> , Vol. 19 (1978) pp 260-266.	<u></u>

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



## SUBMISSION UNDER MPEP 609 D

Page 1 of 1

T	1 00/004 505
Application Number	09/621,565
Filing Date	07/21/2000
First Named Inventor	Miri Seiberg
Group Art Unit	1615
Examiner Name	Blessing M. Fubara
Attorney Docket Number	JBP0510

U.S. PATENT DOCUMENTS

			U.S. Patent Document			
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Filing Date	Atty Docket No.	
		Halas et al.	10/611,100	07-01-2003	J&J5041	
		Seiberg et al.	09/110,409	07-06-1998	JBP0430	
		Seiberg et al.	10/659,598	09-10-2003	JBP0430CIP	
		Seiberg et al.	6,750,229 / 2002/0065300A1	07-27-1999	JBP0465	
		Seiberg et al.	09/206,249	12-07-1998	JBP0438	
		Seiberg et al.	10/092,810 / 2002/0197244A1	03-07-2002	JBP0586DIV	
***		Liu et al.	09/677,511	09-29-2000	JBP0523CIP	
•		Seiberg et al.	09/698,454	10-27-2000	JBP0518	
		Seiberg et al.	10/108,248 / 2003/0064049A1	03-27-2002	J&J1886CIP	
		Seiberg et al.	10/689,149 / 2004/0062731A1	10-20-2003	J&J1886CIP1	
		Liu et al.	10/370,680 / 2003/0224075A1	02-20-2003	JBP0585	
		Miller et al.	6,555,143 / 2002/0160063A1	02-28-2001	J&J1998	
		Liu et al.	09/796,054 / 2002/0160062A1	02-28-2001	J&J2001	
		Saliou et al.	09/795,762 / 2002/0160061A1	02-28-2001	J&J2002	
		Saliou et al.	10/082,905 / 2002/0192313A1	02-25-2002	J&J2091CIP	

FOREIGN PATENT DOCUMENTS

		TOREIO		DOCUMEN			
Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Foreign Pa	atent Docume	KindCode <sup>5</sup>	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
							-
- <u>-</u>		· · · · · · · · · · · · · · · · · · ·					
		OTHER PRIOR ART - N					
Examiner 's Initials*	Cite No. <sup>1</sup>				T <sup>2</sup>		
-							
					-		

Examiner	, ,	Date	
Signature	_	Considered	